The recent success of obesity treatments, particularly Ozempic (semaglutide) and Mounjaro (tirzepatide), has driven significant interest in glucagon-like peptide-1 receptor (GLP1R) targeting drugs. These therapies have witnessed a 595% increase in licensing deal value between 2019 and 2024 year-to-date (YTD), exceeding $6.2 billion in 2024 YTD alone.
Tag Archive for: metabolic disorders
The company, which is developing peptide therapies for treating endocrine and metabolic disorders, including obesity, said on Monday it was seeking a valuation of up to $482.5 million in its initial public offering in the United States.
The Wegovy drugmaker said it expects the acquisition to be completed in 2023 provided that unspecified development and commercial milestones are met.